Cancer Stem Cell Based Targeted Therapy

Sanjun       Shi; Wenliang       Li

doi:10.2174/138161282617200519100353

Nat Rev Dis Primers Hsieh J.J. 3 17009 2017 10.1038/nrdp.2017.9 Hsieh J.J.; Purdue M.P.; Signoretti S.; Swanton C.; Albiges L.; Schmidinger M.; Heng D.Y.; Larkin J.; Ficarra V.; Renal cell carcinoma. Nat Rev Dis Primers 2017,3(1),17009 JCI Insight Casuscelli J. 2 1 2017 10.1172/jci.insight.92688 Casuscelli J.; Weinhold N.; Gundem G.; Wang L.; Zabor E.C.; Drill E.; Wang P.I.; Nanjangud G.J.; Redzematovic A.; Nargund A.M.; Manley B.J.; Arcila M.E.; Donin N.M.; Cheville J.C.; Thompson R.H.; Pantuck A.J.; Russo P.; Cheng E.H.; Lee W.; Tickoo S.K.; Ostrovnaya I.; Creighton C.J.; Papaemmanuil E.; Seshan V.E.; Hakimi A.A.; Hsieh J.J.; Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma. JCI Insight 2017,2(12),1-15 CA Cancer J Clin Siegel R.L. 68 7 2018 10.3322/caac.21442 Siegel R.L.; Miller K.D.; Jemal A.; Cancer statistics, 2018. CA Cancer J Clin 2018,68(1),7-30 Nat Rev Nephrol Posadas E.M. 13 496 2017 10.1038/nrneph.2017.82 Posadas E.M.; Limvorasak S.; Figlin R.A.; Targeted therapies for renal cell carcinoma. Nat Rev Nephrol 2017,13(8),496-511 CA Cancer J Clin Bray F. 68 394 2018 10.3322/caac.21492 Bray F.; Ferlay J.; Soerjomataram I.; Siegel R.L.; Torre L.A.; Jemal A.; Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018,68(6),394-424 Front Oncol Fidler M.M. 8 293 2018 10.3389/fonc.2018.00293 Fidler M.M.; Bray F.; Global cancer inequalities. Front Oncol 2018,8(293),293 Curr Opin Oncol Su D. 26 321 2014 10.1097/CCO.0000000000000069 Su D.; Stamatakis L.; Singer E.A.; Srinivasan R.; Renal cell carcinoma: molecular biology and targeted therapy. Curr Opin Oncol 2014,26(3),321-327 Cancer Treat Rev Gupta K. 34 193 2008 10.1016/j.ctrv.2007.12.001 Gupta K.; Miller J.D.; Li J.Z.; Russell M.W.; Charbonneau C.; Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 2008,34(3),193-205 J Cancer Res Clin Oncol Rasti A. 143 95 2017 10.1007/s00432-016-2239-8 Rasti A.; Abolhasani M.; Zanjani L.S.; Asgari M.; Mehrazma M.; Madjd Z.; Reduced expression of CXCR4, a novel renal cancer stem cell marker, is associated with high-grade renal cell carcinoma. J Cancer Res Clin Oncol 2017,143(1),95-104 Front Oncol Bielecka Z.F. 4 194 2014 10.3389/fonc.2014.00194 Bielecka Z.F.; Czarnecka A.M.; Szczylik C.; Genomic analysis as the first step toward personalized treatment in renal cell carcinoma. Front Oncol 2014,4(194),194 Cancers (Basel) Xu Q. 8 1 2016 10.3390/cancers8060057 Xu Q.; Krause M.; Samoylenko A.; Vainio S.; Wnt signaling in renal cell carcinoma. Cancers (Basel) 2016,8(6),1-14 Oncogenesis Qian W. 7 24 2018 10.1038/s41389-018-0029-7 Qian W.; Kong X.; Zhang T.; Wang D.; Song J.; Li Y.; Li X.; Geng H.; Min J.; Kong Q.; Liu J.; Liu Z.; Wang D.; Zhang Z.; Yu D.; Zhong C.; Cigarette smoke stimulates the stemness of renal cancer stem cells via Sonic Hedgehog pathway. Oncogenesis 2018,7(3),24 Stem Cell Investig Venkatesh V. 5 5 2018 10.21037/sci.2018.02.02 Venkatesh V.; Nataraj R.; Thangaraj G.S.; Karthikeyan M.; Gnanasekaran A.; Kaginelli S.B.; Kuppanna G.; Kallappa C.G.; Basalingappa K.M.; Targeting Notch signalling pathway of cancer stem cells. Stem Cell Investig 2018,5(3),5 Oncotarget Huang R. 8 35351 2017 10.18632/oncotarget.10169 Huang R.; Rofstad E.K.; Cancer stem cells (CSCs), cervical CSCs and targeted therapies. Oncotarget 2017,8(21),35351-35367 Urologia Lucarelli G. 82 46 2015 10.5301/uro.5000099 Lucarelli G.; Galleggiante V.; Rutigliano M.; Vavallo A.; Ditonno P.; Battaglia M.; Isolation and characterization of cancer stem cells in renal cell carcinoma. Urologia 2015,82(1),46-53 J Pathol Clin Res Corrò C. 4 3 2018 10.1002/cjp2.91 Corrò C.; Moch H.; Biomarker discovery for renal cancer stem cells. J Pathol Clin Res 2018,4(1),3-18 Int J Nanomedicine Li J. 13 4607 2018 10.2147/IJN.S168660 Li J.; You J.; Wu C.; Dai Y.; Shi M.; Dong L.; Xu K.; T-T molecular magnetic resonance imaging of renal carcinoma cells based on nano-contrast agents. Int J Nanomedicine 2018,13,4607-4625 Front Pharmacol Yuan Z.X. 7 423 2016 10.3389/fphar.2016.00423 Yuan Z.X.; Mo J.; Zhao G.; Shu G.; Fu H.L.; Zhao W.; Targeting strategies for renal cell carcinoma: from renal cancer cells to renal cancer stem cells. Front Pharmacol 2016,7(194),423 J Am Soc Nephrol Lazzeri E. 18 3128 2007 10.1681/ASN.2007020210 Lazzeri E.; Crescioli C.; Ronconi E.; Mazzinghi B.; Sagrinati C.; Netti G.S.; Angelotti M.L.; Parente E.; Ballerini L.; Cosmi L.; Maggi L.; Gesualdo L.; Rotondi M.; Annunziato F.; Maggi E.; Lasagni L.; Serio M.; Romagnani S.; Vannelli G.B.; Romagnani P.; Regenerative potential of embryonic renal multipotent progenitors in acute renal failure. J Am Soc Nephrol 2007,18(12),3128-3138 J Am Soc Nephrol Oliver J.A. 20 2315 2009 10.1681/ASN.2008111203 Oliver J.A.; Klinakis A.; Cheema F.H.; Friedlander J.; Sampogna R.V.; Martens T.P.; Liu C.; Efstratiadis A.; Al-Awqati Q.; Proliferation and migration of label-retaining cells of the kidney papilla. J Am Soc Nephrol 2009,20(11),2315-2327 Kidney Int Patschan D. 71 744 2007 10.1038/sj.ki.5002102 Patschan D.; Michurina T.; Shi H.K.; Dolff S.; Brodsky S.V.; Vasilieva T.; Cohen-Gould L.; Winaver J.; Chander P.N.; Enikolopov G.; Goligorsky M.S.; Normal distribution and medullary-to-cortical shift of Nestin-expressing cells in acute renal ischemia. Kidney Int 2007,71(8),744-754 J Am Soc Nephrol Song J. 22 2256 2011 10.1681/ASN.2011050447 Song J.; Czerniak S.; Wang T.; Ying W.; Carlone D.L.; Breault D.T.; Humphreys B.D.; Characterization and fate of telomerase-expressing epithelia during kidney repair. J Am Soc Nephrol 2011,22(12),2256-2265 Stem Cell Res (Amst) Romagnani P. 12 828 2014 10.1016/j.scr.2013.12.011 Romagnani P.; Remuzzi G.; CD133+ renal stem cells always co-express CD24 in adult human kidney tissue. Stem Cell Res (Amst) 2014,12(3),828-829 Stem Cells Angelotti M.L. 30 1714 2012 10.1002/stem.1130 Angelotti M.L.; Ronconi E.; Ballerini L.; Peired A.; Mazzinghi B.; Sagrinati C.; Parente E.; Gacci M.; Carini M.; Rotondi M.; Fogo A.B.; Lazzeri E.; Lasagni L.; Romagnani P.; Characterization of renal progenitors committed toward tubular lineage and their regenerative potential in renal tubular injury. Stem Cells 2012,30(8),1714-1725 FASEB J Kitamura S. 19 1789 2005 10.1096/fj.05-3942com Kitamura S.; Yamasaki Y.; Kinomura M.; Sugaya T.; Sugiyama H.; Maeshima Y.; Makino H.; Establishment and characterization of renal progenitor like cells from S3 segment of nephron in rat adult kidney. FASEB J 2005,19(13),1789-1797 Contemp Oncol (Pozn) Matak D. 19 A44 2015 10.5114/wo.2014.47128 Matak D.; Szymanski L.; Szczylik C.; Sledziewski R.; Lian F.; Bartnik E.; Sobocinska A.; Czarnecka A.M.; Biology of renal tumour cancer stem cells applied in medicine. Contemp Oncol (Pozn) 2015,19(1A),A44-A51 Cancer stem cells and renal carcinoma 2012 Bussolati B. 211 Bussolati B.; Camussi G.; Cancer stem cells and renal carcinoma 2012 Springer, NY,211-220 Stem Cell Rev Rep Myszczyszyn A. 11 919 2015 10.1007/s12015-015-9611-y Myszczyszyn A.; Czarnecka A.M.; Matak D.; Szymanski L.; Lian F.; Kornakiewicz A.; Bartnik E.; Kukwa W.; Kieda C.; Szczylik C.; The role of hypoxia and cancer stem cells in renal cell carcinoma pathogenesis. Stem Cell Rev Rep 2015,11(6),919-943 Br J Cancer Salcido C.D. 102 1636 2010 10.1038/sj.bjc.6605668 Salcido C.D.; Larochelle A.; Taylor B.J.; Dunbar C.E.; Varticovski L.; Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer. Br J Cancer 2010,102(11),1636-1644 Cancer Res Yun E.J. 75 3078 2015 10.1158/1538-7445.am2015-3078 Yun E.J.; Zhou J.; Lin C.J.; Abstract 3078: Epigenetic regulation of miR-138 confers cancer stem cell characteristics of renal cell carcinoma. Cancer Res 2015,75(15),3078 Iran J Basic Med Sci Salehi P.M. 20 1200 2017 Salehi P.M.; Foroutan T.; Javeri A.; Taha M.F.; Extract of mouse embryonic stem cells induces the expression of pluripotency genes in human adipose tissue-derived stem cells. Iran J Basic Med Sci 2017,20(11),1200-1206 Front Biosci (Schol Ed) Bu Y. 4 819 2012 Bu Y.; Cao D.; The origin of cancer stem cells. Front Biosci (Schol Ed) 2012,4(3),819-830 Oncotarget Hasmim M. 7 15507 2016 10.18632/oncotarget.6266 Hasmim M.; Bruno S.; Azzi S.; Gallerne C.; Michel J.G.; Chiabotto G.; Lecoz V.; Romei C.; Spaggiari G.M.; Pezzolo A.; Pistoia V.; Angevin E.; Gad S.; Ferlicot S.; Messai Y.; Kieda C.; Clay D.; Sabatini F.; Escudier B.; Camussi G.; Eid P.; Azzarone B.; Chouaib S.; Isolation and characterization of renal cancer stem cells from patient-derived xenografts. Oncotarget 2016,7(13),15507-15524 FASEB J Bussolati B. 22 3696 2008 10.1096/fj.08-102590 Bussolati B.; Bruno S.; Grange C.; Ferrando U.; Camussi G.; Identification of a tumor-initiating stem cell population in human renal carcinomas. FASEB J 2008,22(10),3696-3705 PLoS One Ueda K. 8 2013 10.1371/journal.pone.0075463 Ueda K.; Ogasawara S.; Akiba J.; Nakayama M.; Todoroki K.; Ueda K.; Sanada S.; Suekane S.; Noguchi M.; Matsuoka K.; Yano H.; Aldehyde dehydrogenase 1 identifies cells with cancer stem cell-like properties in a human renal cell carcinoma cell line. PLoS One 2013,8(10) Curr Signal Transduct Ther Khan M.I. 8 240 2014 10.2174/1574362409666140206222431 Khan M.I.; Czarnecka A.M.; Duchnowska R.; Kukwa W.; Szczylik C.; Metastasis-initiating cells in renal cancer. Curr Signal Transduct Ther 2014,8(3),240-246 Cancer Res Smith B.H. 71 716 2011 10.1158/0008-5472.CAN-10-2254 Smith B.H.; Gazda L.S.; Conn B.L.; Jain K.; Asina S.; Levine D.M.; Parker T.S.; Laramore M.A.; Martis P.C.; Vinerean H.V.; David E.M.; Qiu S.; Cordon-Cardo C.; Hall R.D.; Gordon B.R.; Diehl C.H.; Stenzel K.H.; Rubin A.L.; Three-dimensional culture of mouse renal carcinoma cells in agarose macrobeads selects for a subpopulation of cells with cancer stem cell or cancer progenitor properties. Cancer Res 2011,71(3),716-724 Cancer Letters Zhong Y. 299 160 2010 10.1016/j.canlet.2010.08.013 Zhong Y.; Guan K.; Guo S.; Zhou C.; Wang D.; Ma W.; Zhang Y.; Li C.; Zhang S.; Spheres derived from the human SK-RC-42 renal cell carcinoma cell line are enriched in cancer stem cells. Cancer Letters 2010,299(2),160 Oncotarget Lichner Z. 6 5567 2015 10.18632/oncotarget.1901 Lichner Z.; Saleh C.; Subramaniam V.; Seivwright A.; Prud’homme G.J.; Yousef G.M.; miR-17 inhibition enhances the formation of kidney cancer spheres with stem cell/ tumor initiating cell properties. Oncotarget 2015,6(8),5567-5581 J Exp Clin Cancer Res Xiao W. 36 41 2017 10.1186/s13046-017-0507-3 Xiao W.; Gao Z.; Duan Y.; Yuan W.; Ke Y.; Notch signaling plays a crucial role in cancer stem-like cells maintaining stemness and mediating chemotaxis in renal cell carcinoma. J Exp Clin Cancer Res 2017,36(1),41 Curr Signal Transduct Ther Kaminska B. 8 180 2014 10.2174/1574362409666140206221621 Kaminska B.; Kulesza D.W.; Ramji K.; Overview of mechanisms of cancer stem cell drug resistance. Curr Signal Transduct Ther 2014,8(3),180-192 Int J Stem Cells Kim Y. 2 109 2009 10.15283/ijsc.2009.2.2.109 Kim Y.; Joo K.M.; Jin J.; Nam D.H.; Cancer stem cells and their mechanism of chemo-radiation resistance. Int J Stem Cells 2009,2(2),109-114 Oncol Rep Czarnecka A.M. 35 1433 2016 10.3892/or.2015.4514 Czarnecka A.M.; Solarek W.; Kornakiewicz A.; Szczylik C.; Tyrosine kinase inhibitors target cancer stem cells in renal cell cancer. Oncol Rep 2016,35(3),1433-1442 Nanomedicine (Lond) Vinogradov S. 7 597 2012 10.2217/nnm.12.22 Vinogradov S.; Wei X.; Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine (Lond) 2012,7(4),597-615 Curr Opin Oncol Mier J.W. 31 194 2019 10.1097/CCO.0000000000000512 Mier J.W.; The tumor microenvironment in renal cell cancer. Curr Opin Oncol 2019,31(3),194-199 Br J Cancer Frödin M. 116 195 2017 10.1038/bjc.2016.407 Frödin M.; Mezheyeuski A.; Corvigno S.; Harmenberg U.; Sandström P.; Egevad L.; Johansson M.; Östman A.; Perivascular PDGFR-β is an independent marker for prognosis in renal cell carcinoma. Br J Cancer 2017,116(2),195-201 Fujita K 215 2017 Fujita K; Tumor Angiogenesis MA; A focus on the role of cancer stem cells. physiologic and pathologic angiogenesis - signaling mechanisms and targeted therapy 2017,215-25 BMB Rep Chae Y.C. 51 319 2018 10.5483/BMBRep.2018.51.7.112 Chae Y.C.; Kim J.H.; Cancer stem cell metabolism: target for cancer therapy. BMB Rep 2018,51(7),319-326 Oncol Lett Wang Y. 14 8150 2017 10.3892/ol.2017.7238 Wang Y.; Li C.; Li Y.; Zhu Z.; Involvement of breast cancer stem cells in tumor angiogenesis. Oncol Lett 2017,14(6),8150-8155 Pathol Oncol Res Ruiz-Saurí A. 24 515 2018 10.1007/s12253-017-0262-y Ruiz-Saurí A.; García-Bustos V.; Granero E.; Cuesta S.; Sales M.A.; Marcos V.; Llombart-Bosch A.; Distribution of vascular patterns in different subtypes of renal cell carcinoma. a morphometric study in two distinct types of blood vessels. Pathol Oncol Res 2018,24(3),515-524 J Surg Oncol Zhang Y. 108 414 2013 10.1002/jso.23402 Zhang Y.; Sun B.; Zhao X.; Liu Z.; Wang X.; Yao X.; Dong X.; Chi J.; Clinical significances and prognostic value of cancer stem-like cells markers and vasculogenic mimicry in renal cell carcinoma. J Surg Oncol 2013,108(6),414-419 Cancer Qian C.N. 115 2282 2009 10.1002/cncr.24238 Qian C.N.; Huang D.; Wondergem B.; Teh B.T.; Complexity of tumor vasculature in clear cell renal cell carcinoma. Cancer 2009,115(10)(Suppl.),2282-2289 Cancer Lett Yao H. 379 213 2016 10.1016/j.canlet.2016.03.014 Yao H.; Liu N.; Lin M.C.; Zheng J.; Positive feedback loop between cancer stem cells and angiogenesis in hepatocellular carcinoma. Cancer Lett 2016,379(2),213-219 Cancer Res Berlato C. 74 1076 2014 Berlato C.; Kahn M.N.; Schioppa T.; Abstract 1076: Antagonists of the chemokine receptor CCR4 reverse the tumor-promoting microenvironment of renal cancer. Cancer Res 2014,74(19),1076 Differentiation Tanigawa S. 91 152 2016 10.1016/j.diff.2016.01.007 Tanigawa S.; Perantoni A.O.; Modeling renal progenitors - defining the niche. Differentiation 2016,91(4-5),152-158 Biomarkers Med Lan J. 10 919 2016 10.2217/bmm-2016-0026 Lan J.; Li J.; Ju X.; Zhou Y.; Qi Y.; Ren Y.; Zou H.; Wang L.; Li M.; Pang L.; Relationship between microvessel density and cancer stem cells in tumor angiogenesis: a meta-analysis. Biomarkers Med 2016,10(8),919-932 Ochsner J Li L. 13 109 2013 Li L.; Cole J.; Margolin D.A.; Cancer stem cell and stromal microenvironment. Ochsner J 2013,13(1),109-118 Cancer Biol Ther Banumathy G. 10 658 2010 10.4161/cbt.10.7.13247 Banumathy G.; Cairns P.; Signaling pathways in renal cell carcinoma. Cancer Biol Ther 2010,10(7),658-664 Sci Rep Rasti A. 8 11739 2018 10.1038/s41598-018-30168-4 Rasti A.; Mehrazma M.; Madjd Z.; Abolhasani M.; Saeednejad Zanjani L.; Asgari M.; Co-expression of cancer stem cell markers OCT4 and NANOG predicts poor prognosis in renal cell carcinomas. Sci Rep 2018,8(1),11739 J Cancer Xie Z. 7 1205 2016 10.7150/jca.14604 Xie Z.; Lee Y.H.; Boeke M.; Jilaveanu L.B.; Liu Z.; Bottaro D.P.; Kluger H.M.; Shuch B.; MET inhibition in clear cell renal cell carcinoma. J Cancer 2016,7(10),1205-1214 Kidney Blood Press Res Liu X. 40 288 2015 10.1159/000368504 Liu X.; Wang J.; Sun G.; Identification of key genes and pathways in renal cell carcinoma through expression profiling data. Kidney Blood Press Res 2015,40(3),288-297 Oncotarget Wang D. 5 10803 2014 10.18632/oncotarget.2506 Wang D.; Lu P.; Zhang H.; Luo M.; Zhang X.; Wei X.; Gao J.; Zhao Z.; Liu C.; Oct-4 and Nanog promote the epithelial-mesenchymal transition of breast cancer stem cells and are associated with poor prognosis in breast cancer patients. Oncotarget 2014,5(21),10803-10815 Stem Cells Int Peired A.J. 2016 2016 10.1155/2016/4798639 Peired A.J.; Sisti A.; Romagnani P.; Mesenchymal stem cell-based therapy for kidney disease: a review of clinical evidence. Stem Cells Int 2016,2016(3) Cancer Lett Bussolati B. 338 141 2013 10.1016/j.canlet.2012.05.007 Bussolati B.; Dekel B.; Azzarone B.; Camussi G.; Human renal cancer stem cells. Cancer Lett 2013,338(1),141-146 Stem Cell Reports Hu J. 9 464 2017 10.1016/j.stemcr.2017.07.009 Hu J.; Guan W.; Liu P.; Dai J.; Tang K.; Xiao H.; Qian Y.; Sharrow A.C.; Ye Z.; Wu L.; Xu H.; Endoglin is essential for the maintenance of self-renewal and chemoresistance in renal cancer stem cells. Stem Cell Reports 2017,9(2),464-477 Br J Cancer Saroufim A. 110 1778 2014 10.1038/bjc.2014.71 Saroufim A.; Messai Y.; Hasmim M.; Rioux N.; Iacovelli R.; Verhoest G.; Bensalah K.; Patard J.J.; Albiges L.; Azzarone B.; Escudier B.; Chouaib S.; Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma. Br J Cancer 2014,110(7),1778-1784 Cancer Biomark Saeednejad Zanjani L. 21 821 2018 10.3233/CBM-170755 Saeednejad Zanjani L.; Madjd Z.; Abolhasani M.; Shariftabrizi A.; Rasti A.; Asgari M.; Expression of CD105 cancer stem cell marker in three subtypes of renal cell carcinoma. Cancer Biomark 2018,21(4),821-837 Stem Cell Res Ther Khan M.I. 6 178 2015 10.1186/s13287-015-0177-z Khan M.I.; Czarnecka A.M.; Helbrecht I.; Bartnik E.; Lian F.; Szczylik C.; Current approaches in identification and isolation of human renal cell carcinoma cancer stem cells. Stem Cell Res Ther 2015,6(1),178 J Drug Target Barzegar Behrooz A. 27 257 2019 10.1080/1061186X.2018.1479756 Barzegar Behrooz A.; Syahir A.; Ahmad S.; CD133: beyond a cancer stem cell biomarker. J Drug Target 2019,27(3),257-269 J Pathol Grosse-Gehling P. 229 355 2013 10.1002/path.4086 Grosse-Gehling P.; Fargeas C.A.; Dittfeld C.; Garbe Y.; Alison M.R.; Corbeil D.; Kunz-Schughart L.A.; CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges. J Pathol 2013,229(3),355-378 Am J Pathol Bruno S. 169 2223 2006 10.2353/ajpath.2006.060498 Bruno S.; Bussolati B.; Grange C.; Collino F.; Graziano M.E.; Ferrando U.; Camussi G.; CD133+ renal progenitor cells contribute to tumor angiogenesis. Am J Pathol 2006,169(6),2223-2235 Oncol Lett Kim K. 2 1095 2011 Kim K.; Ihm H.; Ro J.Y.; Cho Y.M.; High-level expression of stem cell marker CD133 in clear cell renal cell carcinoma with favorable prognosis. Oncol Lett 2011,2(6),1095-1100 Curr Med Chem Zhou W. 26 3026 2019 10.2174/0929867324666170830111531 Zhou W.; Guo S.; Liu M.; Burow M.E.; Wang G.; Targeting CXCL12/CXCR4 axis in tumor immunotherapy. Curr Med Chem 2019,26(17),3026-3041 Oncotarget Weiss I.D. 8 73387 2017 10.18632/oncotarget.19945 Weiss I.D.; Huff L.M.; Evbuomwan M.O.; Xu X.; Dang H.D.; Velez D.S.; Singh S.P.; Zhang H.H.; Gardina P.J.; Lee J.H.; Lindenberg L.; Myers T.G.; Paik C.H.; Schrump D.S.; Pittaluga S.; Choyke P.L.; Fojo T.; Farber J.M.; Screening of cancer tissue arrays identifies CXCR4 on adrenocortical carcinoma: correlates with expression and quantification on metastases using Cu-plerixafor PET. Oncotarget 2017,8(43),73387-73406 Stem Cells Gassenmaier M. 31 1467 2013 10.1002/stem.1407 Gassenmaier M.; Chen D.; Buchner A.; Henkel L.; Schiemann M.; Mack B.; Schendel D.J.; Zimmermann W.; Pohla H.; CXC chemokine receptor 4 is essential for maintenance of renal cell carcinoma-initiating cells and predicts metastasis. Stem Cells 2013,31(8),1467-1476 Stem Cells Inter Peired A.J. 2016 1 2016 10.1155/2016/4798639 Peired A.J.; Sisti A.; Romagnani P.; Mesenchymal stem cell-based therapy for kidney disease: a review of clinical evidence. Stem Cells Inter 2016,2016(3),1-22 Cell Cycle D’Alterio C. 9 4492 2010 10.4161/cc.9.22.13680 D’Alterio C.; Cindolo L.; Portella L.; Polimeno M.; Consales C.; Riccio A.; Cioffi M.; Franco R.; Chiodini P.; Cartenì G.; Mirone V.; Longo N.; Marra L.; Perdonà S.; Claudio L.; Mascolo M.; Staibano S.; Falsaperla M.; Puglisi M.; Martignoni G.; Ficarra V.; Castello G.; Scala S.; Differential role of CD133 and CXCR4 in renal cell carcinoma. Cell Cycle 2010,9(22),4492-4500 Cancer Lett Weitzenfeld P. 352 36 2014 10.1016/j.canlet.2013.10.006 Weitzenfeld P.; Ben-Baruch A.; The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer. Cancer Lett 2014,352(1),36-53 Oncotarget Tomita H. 7 11018 2016 10.18632/oncotarget.6920 Tomita H.; Tanaka K.; Tanaka T.; Hara A.; Aldehyde dehydrogenase 1A1 in stem cells and cancer. Oncotarget 2016,7(10),11018-11032 Med Oncol Wang K. 30 574 2013 10.1007/s12032-013-0574-z Wang K.; Chen X.; Zhan Y.; Jiang W.; Liu X.; Wang X.; Wu B.; Increased expression of ALDH1A1 protein is associated with poor prognosis in clear cell renal cell carcinoma. Med Oncol 2013,30(2),574 Oncogene Schoenfeld D. 76 24 2016 10.1158/1538-7445.chromepi15-a24 Schoenfeld D.; Su W.; Zairis S.; Abstract A24: PBRM1 alteration in clear cell renal cell carcinoma increases tumorigenicity through ALDH1A1 upregulation. Oncogene 2016,76(2),24 Saudi Med J Basakran N.S. 36 273 2015 10.15537/smj.2015.3.9622 Basakran N.S.; CD44 as a potential diagnostic tumor marker. Saudi Med J 2015,36(3),273-279 Stem Cells Int Peired A.J. 2016 2016 10.1155/2016/8342625 Peired A.J.; Sisti A.; Romagnani P.; Renal cancer stem cells: characterization and targeted therapies. Stem Cells Int 2016,2016(12) Arkh Patol Moskvina L.V. 75 3 2013 Moskvina L.V.; Andreeva IuI.u.; Frank G.A.; Zavalishina L.É.; Petrov A.N.; Mal’kov P.G.; [Prognostic value of the expression of adhesion molecules for non-clear-cell variants of renal cell carcinoma]. Arkh Patol 2013,75(4),3-8 Int J Cancer Mikami S. 136 1504 2015 10.1002/ijc.29137 Mikami S.; Mizuno R.; Kosaka T.; Saya H.; Oya M.; Okada Y.; Expression of TNF-α and CD44 is implicated in poor prognosis, cancer cell invasion, metastasis and resistance to the sunitinib treatment in clear cell renal cell carcinomas. Int J Cancer 2015,136(7),1504-1514 Mol Cancer Debeb B.G. 9 180 2010 10.1186/1476-4598-9-180 Debeb B.G.; Zhang X.; Krishnamurthy S.; Gao H.; Cohen E.; Li L.; Rodriguez A.A.; Landis M.D.; Lucci A.; Ueno N.T.; Robertson F.; Xu W.; Lacerda L.; Buchholz T.A.; Cristofanilli M.; Reuben J.M.; Lewis M.T.; Woodward W.A.; Characterizing cancer cells with cancer stem cell-like features in 293T human embryonic kidney cells. Mol Cancer 2010,9(1),180 Oncotarget Cheng B. 7 65862 2016 10.18632/oncotarget.11672 Cheng B.; Yang G.; Jiang R.; Cheng Y.; Yang H.; Pei L.; Qiu X.; Cancer stem cell markers predict a poor prognosis in renal cell carcinoma: a meta-analysis. Oncotarget 2016,7(40),65862-65875 Cancer Sci Ma C. 107 700 2016 10.1111/cas.12917 Ma C.; Komohara Y.; Ohnishi K.; Shimoji T.; Kuwahara N.; Sakumura Y.; Matsuishi K.; Fujiwara Y.; Motoshima T.; Takahashi W.; Yamada S.; Kitada S.; Fujimoto N.; Nakayama T.; Eto M.; Takeya M.; Infiltration of tumor-associated macrophages is involved in CD44 expression in clear cell renal cell carcinoma. Cancer Sci 2016,107(5),700-707 J Urol Yu G. 192 1229 2014 10.1016/j.juro.2014.05.094 Yu G.; Li H.; Wang J.; Gumireddy K.; Li A.; Yao W.; Tang K.; Xiao W.; Hu J.; Xiao H.; Lang B.; Ye Z.; Huang Q.; Xu H.; miRNA-34a suppresses cell proliferation and metastasis by targeting CD44 in human renal carcinoma cells. J Urol 2014,192(4),1229-1237 Cell Physiol Biochem Jing X. 48 111 2018 10.1159/000491667 Jing X.; Cui X.; Liang H.; Hao C.; Yang Z.; Li X.; Yang X.; Han C.; CD24 is a potential biomarker for prognosis in human breast carcinoma. Cell Physiol Biochem 2018,48(1),111-119 Clin Lab Wang J.L. 64 497 2018 10.7754/Clin.Lab.2017.171012 Wang J.L.; Guo C.R.; Su W.Y.; Chen Y.X.; Xu J.; Fang J.Y.; CD24 overexpression related to lymph node invasion and poor prognosis of colorectal cancer. Clin Lab 2018,64(4),497-505 Clin Dev Immunol Jaggupilli A. 2012 2012 10.1155/2012/708036 Jaggupilli A.; Elkord E.; Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin Dev Immunol 2012,2012(1) Pathol Oncol Res Arik D. 23 409 2017 10.1007/s12253-016-0128-8 Arik D.; Can C.; Dündar E.; Kabukçuoğlu S.; Paşaoğlu Ö.; Prognostic Significance of CD24 in Clear Cell Renal Cell Carcinoma. Pathol Oncol Res 2017,23(2),409-416 Mol Med Rep Cao J. 13 75 2016 10.3892/mmr.2015.4568 Cao J.; Liu J.; Xu R.; Zhu X.; Liu L.; Zhao X.; MicroRNA-21 stimulates epithelial-to-mesenchymal transition and tumorigenesis in clear cell renal cells. Mol Med Rep 2016,13(1),75-82 Eur Rev Med Pharmacol Sci Chen J. 21 4566 2017 Chen J.; Gu Y.; Shen W.; MicroRNA-21 functions as an oncogene and promotes cell proliferation and invasion via TIMP3 in renal cancer. Eur Rev Med Pharmacol Sci 2017,21(20),4566-4576 Biol Chem Papadopoulos E.I. 397 529 2016 10.1515/hsz-2015-0284 Papadopoulos E.I.; Petraki C.; Gregorakis A.; Fragoulis E.G.; Scorilas A.; Clinical evaluation of microRNA-145 expression in renal cell carcinoma: a promising molecular marker for discriminating and staging the clear cell histological subtype. Biol Chem 2016,397(6),529-539 Int J Mol Med Li J. 41 1021 2018 10.3892/ijmm.2017.3269 Li J.; Li C.; Li H.; Zhang T.; Hao X.; Chang J.; Xu Y.; MicroRNA‑30a‑5p suppresses tumor cell proliferation of human renal cancer via the MTDH/PTEN/AKT pathway. Int J Mol Med 2018,41(2),1021-1029 J Clin Pathol Khella H.W.Z. 70 854 2017 10.1136/jclinpath-2017-204341 Khella H.W.Z.; Daniel N.; Youssef L.; Scorilas A.; Nofech-Mozes R.; Mirham L.; Krylov S.N.; Liandeau E.; Krizova A.; Finelli A.; Cheng Y.; Yousef G.M.; miR-10b is a prognostic marker in clear cell renal cell carcinoma. J Clin Pathol 2017,70(10),854-859 BioEssays Blinka S. 39 1 2017 10.1002/bies.201700086 Blinka S.; Rao S.; Nanog expression in embryonic stem cells - an ideal model system to dissect enhancer function. BioEssays 2017,39(12),1-23 J Clin Pathol van Schaijik B. 71 88 2018 10.1136/jclinpath-2017-204815 van Schaijik B.; Davis P.F.; Wickremesekera A.C.; Tan S.T.; Itinteang T.; Subcellular localisation of the stem cell markers OCT4, SOX2, NANOG, KLF4 and c-MYC in cancer: a review. J Clin Pathol 2018,71(1),88-91 Artif Cells Nanomed Biotechnol Yu B. 44 1818 2016 10.3109/21691401.2015.1105238 Yu B.; Cai H.; Xu Z.; Xu T.; Zou Q.; Gu M.; Expressions of stem cell transcription factors Nanog and Oct4 in renal cell carcinoma tissues and clinical significance. Artif Cells Nanomed Biotechnol 2016,44(8),1818-1823 BioMed Res Int Gao Z.W. 2014 2014 10.1155/2014/460654 Gao Z.W.; Dong K.; Zhang H.Z.; The roles of CD73 in cancer. BioMed Res Int 2014,2014(4) Oncotarget Song L. 8 31977 2017 10.18632/oncotarget.16667 Song L.; Ye W.; Cui Y.; Lu J.; Zhang Y.; Ding N.; Hu W.; Pei H.; Yue Z.; Zhou G.; Ecto-5′-nucleotidase (CD73) is a biomarker for clear cell renal carcinoma stem-like cells. Oncotarget 2017,8(19),31977-31992 BMC Cancer Grange C. 15 1009 2015 10.1186/s12885-015-2025-z Grange C.; Tapparo M.; Tritta S.; Deregibus M.C.; Battaglia A.; Gontero P.; Frea B.; Camussi G.; Role of HLA-G and extracellular vesicles in renal cancer stem cell-induced inhibition of dendritic cell differentiation. BMC Cancer 2015,15(1),1009 University of Oxford Earwaker P. 2015 Earwaker P.; Resistance mechanisms to mTOR inhibition in renal cancer. University of Oxford Available at:2015 Oncotarget Brossa A. 6 11295 2015 10.18632/oncotarget.3123 Brossa A.; Grange C.; Mancuso L.; Annaratone L.; Satolli M.A.; Mazzone M.; Camussi G.; Bussolati B.; Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation. Oncotarget 2015,6(13),11295-11309 Nat Rev Mol Cell Biol Trusolino L. 11 834 2010 10.1038/nrm3012 Trusolino L.; Bertotti A.; Comoglio P.M.; MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010,11(12),834-848 Cell Biosci Bielecka Z.F. 7 71 2017 10.1186/s13578-017-0197-8 Bielecka Z.F.; Malinowska A.; Brodaczewska K.K.; Klemba A.; Kieda C.; Krasowski P.; Grzesiuk E.; Piwowarski J.; Czarnecka A.M.; Szczylik C.; Hypoxic 3D in vitro culture models reveal distinct resistance processes to TKIs in renal cancer cells. Cell Biosci 2017,7(1),71 Mol Cancer Ther Ciamporcero E. 14 101 2015 10.1158/1535-7163.MCT-14-0094 Ciamporcero E.; Miles K.M.; Adelaiye R.; Ramakrishnan S.; Shen L.; Ku S.; Pizzimenti S.; Sennino B.; Barrera G.; Pili R.; Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models. Mol Cancer Ther 2015,14(1),101-110 Memo Pichler R. 10 206 2017 10.1007/s12254-017-0344-2 Pichler R.; Heidegger I.; Novel concepts of antiangiogenic therapies in metastatic renal cell cancer. Memo 2017,10(4),206-212 Cancer Cell Int Lai Y. 18 31 2018 10.1186/s12935-018-0530-2 Lai Y.; Zhao Z.; Zeng T.; Liang X.; Chen D.; Duan X.; Zeng G.; Wu W.; Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma. Cancer Cell Int 2018,18(1),31 Expert Opin Investig Drugs Ghidini M. 26 1229 2017 10.1080/13543784.2017.1384813 Ghidini M.; Petrelli F.; Ghidini A.; Tomasello G.; Hahne J.C.; Passalacqua R.; Barni S.; Clinical development of mTor inhibitors for renal cancer. Expert Opin Investig Drugs 2017,26(11),1229-1237 Sci Signal Katsuno Y. 12 1 2019 10.1126/scisignal.aau8544 Katsuno Y.; Meyer D.S.; Zhang Z.; Shokat K.M.; Akhurst R.J.; Miyazono K.; Derynck R.; Chronic TGF-β exposure drives stabilized EMT, tumor stemness, and cancer drug resistance with vulnerability to bitopic mTOR inhibition. Sci Signal 2019,12(570),1-17 Am J Cancer Res Xia P. 5 1602 2015 Xia P.; Xu X.Y.; PI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical application. Am J Cancer Res 2015,5(5),1602-1609 Br J Clin Pharmacol Francipane M.G. 82 1180 2016 10.1111/bcp.12844 Francipane M.G.; Lagasse E.; Therapeutic potential of mTOR inhibitors for targeting cancer stem cells. Br J Clin Pharmacol 2016,82(5),1180-1188 EMBO Mol Med Smith K.M. 2 371 2010 10.1002/emmm.201000093 Smith K.M.; Datti A.; Fujitani M.; Grinshtein N.; Zhang L.; Morozova O.; Blakely K.M.; Rotenberg S.A.; Hansford L.M.; Miller F.D.; Yeger H.; Irwin M.S.; Moffat J.; Marra M.A.; Baruchel S.; Wrana J.L.; Kaplan D.R.; Selective targeting of neuroblastoma tumour-initiating cells by compounds identified in stem cell-based small molecule screens. EMBO Mol Med 2010,2(9),371-384 Oncotarget Sharma N. 6 32039 2015 10.18632/oncotarget.5055 Sharma N.; Nanta R.; Sharma J.; Gunewardena S.; Singh K.P.; Shankar S.; Srivastava R.K.; PI3K/AKT/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth. Oncotarget 2015,6(31),32039-32060 Int J Oncol Yang C. 47 909 2015 10.3892/ijo.2015.3100 Yang C.; Zhang Y.; Zhang Y.; Zhang Z.; Peng J.; Li Z.; Han L.; You Q.; Chen X.; Rao X.; Zhu Y.; Liao Z.; Downregulation of cancer stem cell properties via mTOR signaling pathway inhibition by rapamycin in nasopharyngeal carcinoma. Int J Oncol 2015,47(3),909-917 Clin Exp Pharmacol Physiol Chen J. 42 1317 2015 10.1111/1440-1681.12493 Chen J.; Shao R.; Li F.; Monteiro M.; Liu J.P.; Xu Z.P.; Gu W.; PI3K/Akt/mTOR pathway dual inhibitor BEZ235 suppresses the stemness of colon cancer stem cells. Clin Exp Pharmacol Physiol 2015,42(12),1317-1326 Future Oncol Czarnecka A.M. 11 801 2015 10.2217/fon.14.303 Czarnecka A.M.; Kornakiewicz A.; Lian F.; Szczylik C.; Future perspectives for mTOR inhibitors in renal cell cancer treatment. Future Oncol 2015,11(5),801-817 Clin Cancer Res Cho D.C. 16 3628 2010 10.1158/1078-0432.CCR-09-3022 Cho D.C.; Cohen M.B.; Panka D.J.; Collins M.; Ghebremichael M.; Atkins M.B.; Signoretti S.; Mier J.W.; The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res 2010,16(14),3628-3638 Lancet Oncol Motzer R.J. 16 1473 2015 10.1016/S1470-2045(15)00290-9 Motzer R.J.; Hutson T.E.; Glen H.; Michaelson M.D.; Molina A.; Eisen T.; Jassem J.; Zolnierek J.; Maroto J.P.; Mellado B.; Melichar B.; Tomasek J.; Kremer A.; Kim H.J.; Wood K.; Dutcus C.; Larkin J.; Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 2015,16(15),1473-1482 J Natl Cancer Inst Azzi S. 103 1884 2011 10.1093/jnci/djr451 Azzi S.; Bruno S.; Giron-Michel J.; Clay D.; Devocelle A.; Croce M.; Ferrini S.; Chouaib S.; Vazquez A.; Charpentier B.; Camussi G.; Azzarone B.; Eid P.; Differentiation therapy: targeting human renal cancer stem cells with interleukin 15. J Natl Cancer Inst 2011,103(24),1884-1898 Clin Cancer Res Fay A.P. 20 3361 2014 10.1158/1078-0432.CCR-14-0690 Fay A.P.; Signoretti S.; Choueiri T.K.; MET as a target in papillary renal cell carcinoma. Clin Cancer Res 2014,20(13),3361-3363 J Biol Chem Balan M. 290 8110 2015 10.1074/jbc.M114.612689 Balan M.; Mier y Teran E.; Waaga-Gasser A.M.; Gasser M.; Choueiri T.K.; Freeman G.; Pal S.; Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression. J Biol Chem 2015,290(13),8110-8120 Cancer J Harshman L.C. 19 316 2013 10.1097/PPO.0b013e31829e3c9a Harshman L.C.; Choueiri T.K.; Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma. Cancer J 2013,19(4),316-323 Transl Oncogenomics Garajová I. 7 13 2015 Garajová I.; Giovannetti E.; Biasco G.; Peters G.J.; c-Met as a Target for Personalized Therapy. Transl Oncogenomics 2015,7(1)(Suppl. 1),13-31 Biomedicines Zhang Y. 3 149 2015 10.3390/biomedicines3010149 Zhang Y.; Jain R.K.; Zhu M.; Recent progress and advances in HGF/MET-targeted therapeutic agents for cancer treatment. Biomedicines 2015,3(1),149-181 Cell Death Dis Papa E. 8 3210 2017 10.1038/s41419-017-0051-2 Papa E.; Weller M.; Weiss T.; Ventura E.; Burghardt I.; Szabó E.; Negative control of the HGF/c-MET pathway by TGF-β: a new look at the regulation of stemness in glioblastoma. Cell Death Dis 2017,8(12),3210 Tumour Biol Huang J. 35 5833 2014 10.1007/s13277-014-1774-7 Huang J.; Dong B.; Zhang J.; Kong W.; Chen Y.; Xue W.; Liu D.; Huang Y.; miR-199a-3p inhibits hepatocyte growth factor/c-Met signaling in renal cancer carcinoma. Tumour Biol 2014,35(6),5833-5843 OncoTargets Ther Parikh R.A. 7 969 2014 10.2147/OTT.S40241 Parikh R.A.; Wang P.; Beumer J.H.; Chu E.; Appleman L.J.; The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment. OncoTargets Ther 2014,7,969-983 Future Oncol Viola D. 9 1083 2013 10.2217/fon.13.128 Viola D.; Cappagli V.; Elisei R.; Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer. Future Oncol 2013,9(8),1083-1092 Invest New Drugs Ooka Y. 32 723 2014 10.1007/s10637-014-0077-6 Ooka Y.; Chiba T.; Ogasawara S.; Arai K.; Suzuki E.; Tawada A.; Yamashita T.; Kanai F.; Kaneko S.; Yokosuka O.; A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma. Invest New Drugs 2014,32(4),723-728 Curr Oncol Rep Logan T.F. 15 83 2013 10.1007/s11912-013-0299-3 Logan T.F.; Foretinib (XL880): c-MET inhibitor with activity in papillary renal cell cancer. Curr Oncol Rep 2013,15(2),83-90 Oncotarget D’Amico L. 7 45525 2016 10.18632/oncotarget.9997 D’Amico L.; Belisario D.; Migliardi G.; Grange C.; Bussolati B.; D’Amelio P.; Perera T.; Dalmasso E.; Dalle Carbonare L.; Godio L.; Comoglio P.; Trusolino L.; Ferracini R.; Roato I.; C-met inhibition blocks bone metastasis development induced by renal cancer stem cells. Oncotarget 2016,7(29),45525-45537 Int J Mol Sci Kruck S. 14 10944 2013 10.3390/ijms140610944 Kruck S.; Eyrich C.; Scharpf M.; Sievert K.D.; Fend F.; Stenzl A.; Bedke J.; Impact of an altered Wnt1/β-catenin expression on clinicopathology and prognosis in clear cell renal cell carcinoma. Int J Mol Sci 2013,14(6),10944-10957 Mol Cancer Ther Perotti D. 12 2619 2013 10.1158/1535-7163.MCT-13-0335 Perotti D.; Hohenstein P.; Bongarzone I.; Maschietto M.; Weeks M.; Radice P.; Pritchard-Jones K.; Is Wilms tumor a candidate neoplasia for treatment with WNT/β-catenin pathway modulators?--A report from the renal tumors biology-driven drug development workshop. Mol Cancer Ther 2013,12(12),2619-2627 Springerplus Zhao J. 5 1436 2016 10.1186/s40064-016-3153-x Zhao J.; He Q.; Gong Z.; Chen S.; Cui L.; Niclosamide suppresses renal cell carcinoma by inhibiting Wnt/β-catenin and inducing mitochondrial dysfunctions. Springerplus 2016,5(1),1436 Transl Androl Urol Yi X. 5 166 2016 10.21037/tau.2016.s251 Yi X.; Shen T.; Zhou W.; AB251. 15-oxospiramilactone inhibits human renal cell carcinoma cell tumorigenesis through inhibition of Wnt/β-catenin signaling. Transl Androl Urol 2016,5(1),166-167 Nat Rev Clin Oncol Takebe N. 12 445 2015 10.1038/nrclinonc.2015.61 Takebe N.; Miele L.; Harris P.J.; Jeong W.; Bando H.; Kahn M.; Yang S.X.; Ivy S.P.; Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol 2015,12(8),445-464 Evidence-Based Compl Alter Med 2013 1 2013 10.1155/2013/161628 Ho; J-Y, Hsu; R-J, Wu; C-L et a. Ovatodiolide targets β-catenin signaling in suppressing tumorigenesis and overcoming drug resistance in renal cell carcinoma. Evidence-Based Compl Alter Med 2013,2013(12),1-16 Br J Cancer Hirata H. 108 2070 2013 10.1038/bjc.2013.173 Hirata H.; Ueno K.; Nakajima K.; Tabatabai Z.L.; Hinoda Y.; Ishii N.; Dahiya R.; Genistein downregulates onco-miR-1260b and inhibits Wnt-signalling in renal cancer cells. Br J Cancer 2013,108(10),2070-2078 Am J Cancer Res Xiong S. 8 302 2018 Xiong S.; Wang R.; Chen Q.; Luo J.; Wang J.; Zhao Z.; Li Y.; Wang Y.; Wang X.; Cheng B.; Cancer-associated fibroblasts promote stem cell-like properties of hepatocellular carcinoma cells through IL-6/STAT3/Notch signaling. Am J Cancer Res 2018,8(2),302-316 Cancer Res Huang B. 77 3194 2017 10.1158/0008-5472.CAN-16-3146 Huang B.; Yang H.; Cheng X.; Wang D.; Fu S.; Shen W.; Zhang Q.; Zhang L.; Xue Z.; Li Y.; Da Y.; Yang Q.; Li Z.; Liu L.; Qiao L.; Kong Y.; Yao Z.; Zhao P.; Li M.; Zhang R.; tRF/miR-1280 suppresses stem cell-like cells and metastasis in colorectal cancer. Cancer Res 2017,77(12),3194-3206 Oncol Lett Zhuang Z. 14 3437 2017 10.3892/ol.2017.6587 Zhuang Z.; Lin J.; Huang Y.; Lin T.; Zheng Z.; Ma X.; Notch 1 is a valuable therapeutic target against cell survival and proliferation in clear cell renal cell carcinoma. Oncol Lett 2017,14(3),3437-3444 J Biol Chem Bhagat T.D. 292 837 2017 10.1074/jbc.M116.745208 Bhagat T.D.; Zou Y.; Huang S.; Park J.; Palmer M.B.; Hu C.; Li W.; Shenoy N.; Giricz O.; Choudhary G.; Yu Y.; Ko Y.A.; Izquierdo M.C.; Park A.S.; Vallumsetla N.; Laurence R.; Lopez R.; Suzuki M.; Pullman J.; Kaner J.; Gartrell B.; Hakimi A.A.; Greally J.M.; Patel B.; Benhadji K.; Pradhan K.; Verma A.; Susztak K.; Notch pathway is activated via genetic and epigenetic alterations and is a therapeutic target in clear cell renal cancer. J Biol Chem 2017,292(3),837-846 OncoTargets Ther Wu C. 10 3249 2017 10.2147/OTT.S139639 Wu C.; Zhu X.; Liu W.; Ruan T.; Tao K.; Hedgehog signaling pathway in colorectal cancer: function, mechanism, and therapy. OncoTargets Ther 2017,10,3249-3259 Oncol Lett Li E. 18 3081 2019 10.3892/ol.2019.10657 Li E.; Zhang T.; Sun X.; Li Y.; Geng H.; Yu D.; Zhong C.; Sonic hedgehog pathway mediates genistein inhibition of renal cancer stem cells. Oncol Lett 2019,18(3),3081-3091 Bull Exp Biol Med Cherepanov S.A. 164 356 2018 10.1007/s10517-018-3989-x Cherepanov S.A.; Grinenko N.F.; Antonova O.M.; Kurapov P.B.; Shepeleva I.I.; Chekhonin V.P.; Relationship between hedgehog signaling pathway and drug resistance of poorly differentiated gliomas. Bull Exp Biol Med 2018,164(3),356-361 J Am Acad Dermatol Sekulic A. 72 1021 2015 10.1016/j.jaad.2015.03.021 Sekulic A.; Migden M.R.; Lewis K.; Hainsworth J.D.; Solomon J.A.; Yoo S.; Arron S.T.; Friedlander P.A.; Marmur E.; Rudin C.M.; Chang A.L.; Dirix L.; Hou J.; Yue H.; Hauschild A.; Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol 2015,72(6),1021-6.e8 Br J Cancer D’Amato C. 111 1168 2014 10.1038/bjc.2014.421 D’Amato C.; Rosa R.; Marciano R.; D’Amato V.; Formisano L.; Nappi L.; Raimondo L.; Di Mauro C.; Servetto A.; Fulciniti F.; Cipolletta A.; Bianco C.; Ciardiello F.; Veneziani B.M.; De Placido S.; Bianco R.; Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells. Br J Cancer 2014,111(6),1168-1179 Carcinogenesis Dormoy V. 33 2084 2012 10.1093/carcin/bgs255 Dormoy V.; Béraud C.; Lindner V.; Coquard C.; Barthelmebs M.; Brasse D.; Jacqmin D.; Lang H.; Massfelder T.; Vitamin D3 triggers antitumor activity through targeting hedgehog signaling in human renal cell carcinoma. Carcinogenesis 2012,33(11),2084-2093 Curr Oncol Rep Rosen L.S. 16 365 2014 10.1007/s11912-013-0365-x Rosen L.S.; Gordon M.S.; Robert F.; Matei D.E.; Endoglin for targeted cancer treatment. Curr Oncol Rep 2014,16(2),365-482 J Gastrointest Cancer Mohamed S.Y. 50 23 2019 10.1007/s12029-017-0014-y Mohamed S.Y.; Mohammed H.L.; Ibrahim H.M.; Mohamed E.M.; Salah M.; Role of VEGF, CD105, and CD31 in the prognosis of colorectal cancer cases. J Gastrointest Cancer 2019,50(1),23-34 ACS Appl Mater Interfaces Hong H. 7 3373 2015 10.1021/am508440j Hong H.; Wang F.; Zhang Y.; Graves S.A.; Eddine S.B.; Yang Y.; Theuer C.P.; Nickles R.J.; Wang X.; Cai W.; Red fluorescent zinc oxide nanoparticle: a novel platform for cancer targeting. ACS Appl Mater Interfaces 2015,7(5),3373-3381 Oncotarget Brossa A. 9 22680 2018 10.18632/oncotarget.25206 Brossa A.; Buono L.; Bussolati B.; Effect of the monoclonal antibody TRC105 in combination with Sunitinib on renal tumor derived endothelial cells. Oncotarget 2018,9(32),22680-22692 Annal Oncol Choueiri T.K. 27 2016 10.1200/jco.2014.32.15_suppl.e15562 Choueiri T.K.; Michaelson M.D.; Posadas E.M.; A phase 1b dose-escalation study of TRC105 (anti-Endoglin Antibody) in combination with axitinib in patients with metastatic renal cell carcinoma (mRCC). Annal Oncol 2016,27(Suppl. 6) Oncologist Choueiri T.K. 24 202 2019 10.1634/theoncologist.2018-0299 Choueiri T.K.; Michaelson M.D.; Posadas E.M.; Sonpavde G.P.; McDermott D.F.; Nixon A.B.; Liu Y.; Yuan Z.; Seon B.K.; Walsh M.; Jivani M.A.; Adams B.J.; Theuer C.P.; An open label phase Ib dose escalation study of TRC105 (anti-endoglin antibody) with axitinib in patients with metastatic renal cell carcinoma. Oncologist 2019,24(2),202-210 Clin Cancer Res Duffy A.G. 23 4633 2017 10.1158/1078-0432.CCR-16-3171 Duffy A.G.; Ma C.; Ulahannan S.V.; Rahma O.E.; Makarova-Rusher O.; Cao L.; Yu Y.; Kleiner D.E.; Trepel J.; Lee M.J.; Tomita Y.; Steinberg S.M.; Heller T.; Turkbey B.; Choyke P.L.; Peer C.J.; Figg W.D.; Wood B.J.; Greten T.F.; Phase I and preliminary phase II study of TRC105 in combination with sorafenib in hepatocellular carcinoma. Clin Cancer Res 2017,23(16),4633-4641 Cancer Dorff T.B. 123 4566 2017 10.1002/cncr.30942 Dorff T.B.; Longmate J.A.; Pal S.K.; Stadler W.M.; Fishman M.N.; Vaishampayan U.N.; Rao A.; Pinksi J.K.; Hu J.S.; Quinn D.I.; Lara P.N.; Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer. Cancer 2017,123(23),4566-4573 Br J Cancer Micucci C. 113 1178 2015 10.1038/bjc.2015.338 Micucci C.; Matacchione G.; Valli D.; Orciari S.; Catalano A.; HIF2α is involved in the expansion of CXCR4-positive cancer stem-like cells in renal cell carcinoma. Br J Cancer 2015,113(8),1178-1185 Cancer Res Panka D.J. 76 4155 2016 10.1158/1538-7445.AM2016-4155 Panka D.J.; Arbeit R.D.; Mier J.W.; Abstract 4155: Regulation of MDSC trafficking and function in RCC by CXCR4 in the presence of a VEGF-R antagonist. Cancer Res 2016,76(14),4155 Oncol Rep Wang L. 28 2043 2012 10.3892/or.2012.2028 Wang L.; Huang T.; Chen W.; Gao X.; Zhou T.; Wu Z.; Sun Y.; Silencing of CXCR4 by RNA interference inhibits cell growth and metastasis in human renal cancer cells. Oncol Rep 2012,28(6),2043-2048 PLoS One Portella L. 8 2013 10.1371/journal.pone.0074548 Portella L.; Vitale R.; De Luca S.; D’Alterio C.; Ieranò C.; Napolitano M.; Riccio A.; Polimeno M.N.; Monfregola L.; Barbieri A.; Luciano A.; Ciarmiello A.; Arra C.; Castello G.; Amodeo P.; Scala S.; Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases. PLoS One 2013,8(9) Oncotarget Santagata S. 8 77110 2017 10.18632/oncotarget.20363 Santagata S.; Napolitano M.; D’Alterio C.; Desicato S.; Maro S.D.; Marinelli L.; Fragale A.; Buoncervello M.; Persico F.; Gabriele L.; Novellino E.; Longo N.; Pignata S.; Perdonà S.; Scala S.; Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer. Oncotarget 2017,8(44),77110-77120 Mol Cancer Ther Peng S.B. 14 480 2015 10.1158/1535-7163.MCT-14-0850 Peng S.B.; Zhang X.; Paul D.; Kays L.M.; Gough W.; Stewart J.; Uhlik M.T.; Chen Q.; Hui Y.H.; Zamek-Gliszczynski M.J.; Wijsman J.A.; Credille K.M.; Yan L.Z.; Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models. Mol Cancer Ther 2015,14(2),480-490 Target Oncol Hainsworth J.D. 11 643 2016 10.1007/s11523-016-0434-9 Hainsworth J.D.; Reeves J.A.; Mace J.R.; Crane E.J.; Hamid O.; Stille J.R.; Flynt A.; Roberson S.; Polzer J.; Arrowsmith E.R.; A randomized, open-label phase 2 study of the CXCR4 inhibitor LY2510924 in combination with sunitinib Versus sunitinib alone in patients with metastatic renal cell carcinoma (RCC). Target Oncol 2016,11(5),643-653 PLoS One Gironmichel J. 7 1 2012 10.1371/journal.pone.0031624 Gironmichel J.; Azzi S.; Khawam K.; Interleukin-15 plays a central role in human kidney physiology and cancer through the γc signaling pathway. PLoS One 2012,7(2),1-14 Cytokine Growth Factor Rev Giron-Michel J. 24 13 2013 10.1016/j.cytogfr.2012.08.006 Giron-Michel J.; Azzi S.; Ferrini S.; Chouaib S.; Camussi G.; Eid P.; Azzarone B.; Interleukin-15 is a major regulator of the cell-microenvironment interactions in human renal homeostasis. Cytokine Growth Factor Rev 2013,24(1),13-22 J Clin Oncol Conlon K.C. 33 74 2015 10.1200/JCO.2014.57.3329 Conlon K.C.; Lugli E.; Welles H.C.; Rosenberg S.A.; Fojo A.T.; Morris J.C.; Fleisher T.A.; Dubois S.P.; Perera L.P.; Stewart D.M.; Goldman C.K.; Bryant B.R.; Decker J.M.; Chen J.; Worthy T.A.; Figg W.D.; Peer C.J.; Sneller M.C.; Lane H.C.; Yovandich J.L.; Creekmore S.P.; Roederer M.; Waldmann T.A.; Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol 2015,33(1),74-82 Curr Oncol Rep Curtis S.A. 18 57 2016 10.1007/s11912-016-0542-9 Curtis S.A.; Cohen J.V.; Kluger H.M.; Evolving Immunotherapy Approaches for Renal Cell Carcinoma. Curr Oncol Rep 2016,18(9),57 J Onco-Nephrol Derosa L. 1 179 2017 10.5301/jo-n.5000027 Derosa L.; Albiges L.; Escudier B.; Targeting the Pd-1 Pathway in Renal Cell Carcinoma: A Review. J Onco-Nephrol 2017,1(3),179-187 Hum Vaccin Immunother Gill D. 12 2997 2016 10.1080/21645515.2016.1212794 Gill D.; Hahn A.W.; Sonpavde G.; Agarwal N.; Immunotherapy of advanced renal cell carcinoma: Current and future therapies. Hum Vaccin Immunother 2016,12(12),2997-3004 Immunology Codd A.S. 153 304 2018 10.1111/imm.12866 Codd A.S.; Kanaseki T.; Torigo T.; Tabi Z.; Cancer stem cells as targets for immunotherapy. Immunology 2018,153(3),304-314 Expert Opin Biol Ther Luna J.I. 17 313 2017 10.1080/14712598.2017.1271874 Luna J.I.; Grossenbacher S.K.; Murphy W.J.; Canter R.J.; Targeting cancer stem cells with natural killer cell immunotherapy. Expert Opin Biol Ther 2017,17(3),313-324 Mol Carcinog Zhang X.F. 56 2499 2017 10.1002/mc.22697 Zhang X.F.; Weng D.S.; Pan K.; Zhou Z.Q.; Pan Q.Z.; Zhao J.J.; Tang Y.; Jiang S.S.; Chen C.L.; Li Y.Q.; Zhang H.X.; Chang A.E.; Wicha M.S.; Zeng Y.X.; Li Q.; Xia J.C.; Dendritic-cell-based immunotherapy evokes potent anti-tumor immune responses in CD105+ human renal cancer stem cells. Mol Carcinog 2017,56(11),2499-2511 Int J Mol Sci Schanza L.M. 18 1 2017 10.3390/ijms18112495 Schanza L.M.; Seles M.; Stotz M.; Fosselteder J.; Hutterer G.C.; Pichler M.; Stiegelbauer V.; MicroRNAs associated with von hippel-lindau pathway in renal cell carcinoma: a comprehensive review. Int J Mol Sci 2017,18(11),1-12 J Cell Physiol Zhu J. 234 2581 2019 10.1002/jcp.27020 Zhu J.; Zhu D.Q.; Zhang Y.; Liu Q.M.; Wang P.C.; Li H.Z.; Ma X.; Zhang X.; MicroRNA-363 inhibits angiogenesis, proliferation, invasion, and migration of renal cell carcinoma via inactivation of the Janus tyrosine kinases 2-signal transducers and activators of transcription 3 axis by suppressing growth hormone receptor gene. J Cell Physiol 2019,234(3),2581-2592 Oncotarget Yun E.J. 8 66975 2017 10.18632/oncotarget.17756 Yun E.J.; Zhou J.; Lin C.J.; Xu S.; Santoyo J.; Hernandez E.; Lai C.H.; Lin H.; He D.; Hsieh J.T.; The network of DAB2IP-miR-138 in regulating drug resistance of renal cell carcinoma associated with stem-like phenotypes. Oncotarget 2017,8(40),66975-66986 Oncol Lett An F. 14 4684 2017 10.3892/ol.2017.6746 An F.; Liu Y.; Hu Y.; miR-21 inhibition of LATS1 promotes proliferation and metastasis of renal cancer cells and tumor stem cell phenotype. Oncol Lett 2017,14(4),4684-4688 Cancer Res Grange C. 71 5346 2011 10.1158/0008-5472.CAN-11-0241 Grange C.; Tapparo M.; Collino F.; Vitillo L.; Damasco C.; Deregibus M.C.; Tetta C.; Bussolati B.; Camussi G.; Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res 2011,71(15),5346-5356 J Cancer Valera V.A. 2 515 2011 10.7150/jca.2.515 Valera V.A.; Walter B.A.; Linehan W.M.; Merino M.J.; Regulatory effects of microrna-92 (miR-92) on VHL gene expression and the hypoxic activation of miR-210 in clear cell renal cell carcinoma. J Cancer 2011,2(211),515-526 J Cell Biochem Liu G.L. 118 3424 2017 10.1002/jcb.25999 Liu G.L.; Yang H-J.; Liu B.; Liu T.; Effects of MicroRNA-19b on the proliferation, apoptosis, and migration of wilms’ tumor cells via the PTEN/PI3K/AKT signaling pathway. J Cell Biochem 2017,118(10),3424-3434 Biomaterials Shen S. 74 1 2016 10.1016/j.biomaterials.2015.09.037 Shen S.; Xia J.X.; Wang J.; Nanomedicine-mediated cancer stem cell therapy. Biomaterials 2016,74,1-18 Curr Stem Cell Res Ther Xia P. 9 102 2014 10.2174/1574888X09666131217003709 Xia P.; Surface markers of cancer stem cells in solid tumors. Curr Stem Cell Res Ther 2014,9(2),102-111 Nanomedicine (Lond) Kulkarni A.A. 12 1853 2016 10.1016/j.nano.2016.04.002 Kulkarni A.A.; Vijaykumar V.E.; Natarajan S.K.; Sengupta S.; Sabbisetti V.S.; Sustained inhibition of cMET-VEGFR2 signaling using liposome-mediated delivery increases efficacy and reduces toxicity in kidney cancer. Nanomedicine (Lond) 2016,12(7),1853-1861 Biomaterials Yang Q. 146 72 2017 10.1016/j.biomaterials.2017.09.008 Yang Q.; Wang Y.; Yang Q.; Gao Y.; Duan X.; Fu Q.; Chu C.; Pan X.; Cui X.; Sun Y.; Cuprous oxide nanoparticles trigger ER stress-induced apoptosis by regulating copper trafficking and overcoming resistance to sunitinib therapy in renal cancer. Biomaterials 2017,146(5),72-85 Mol Cancer Ther Markovsky E. 16 2462 2017 10.1158/1535-7163.MCT-17-0184 Markovsky E.; Vax E.; Ben-Shushan D.; Eldar-Boock A.; Shukrun R.; Yeini E.; Barshack I.; Caspi R.; Harari-Steinberg O.; Pode-Shakked N.; Dekel B.; Satchi-Fainaro R.; Wilms tumor ncam-expressing cancer stem cells as potential therapeutic target for polymeric nanomedicine. Mol Cancer Ther 2017,16(11),2462-2472 Biomaterials Kang T. 136 98 2017 10.1016/j.biomaterials.2017.05.013 Kang T.; Li F.; Baik S.; Shao W.; Ling D.; Hyeon T.; Surface design of magnetic nanoparticles for stimuli-responsive cancer imaging and therapy. Biomaterials 2017,136,98-114 Sci Rep Min W.K. 7 1 2017 Min W.K.; Jeong H.Y.; Kang S.J.; Cancer-targeted nucleic acid delivery and quantum dot imaging using EGF receptor aptamer-conjugated lipid nanoparticles. Sci Rep 2017,7(1),1-11 Nano Lett Ding H. 19 203 2019 10.1021/acs.nanolett.8b03709 Ding H.; Cai Y.; Gao L.; Liang M.; Miao B.; Wu H.; Liu Y.; Xie N.; Tang A.; Fan K.; Yan X.; Nie G.; Exosome-like nanozyme vesicles for HO-responsive catalytic photoacoustic imaging of xenograft nasopharyngeal carcinoma. Nano Lett 2019,19(1),203-209 Sci Rep Gan B.K. 8 8499 2018 10.1038/s41598-018-26749-y Gan B.K.; Yong C.Y.; Ho K.L.; Omar A.R.; Alitheen N.B.; Tan W.S.; Targeted delivery of cell penetrating peptide virus-like nanoparticles to skin cancer cells. Sci Rep 2018,8(1),8499

Rights & Permissions Print Cite

Article Metrics

9

1

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/138161282617200519100353	Print ISSN 1381-6128
Publisher Name Bentham Science Publisher	Online ISSN 1873-4286

Current Pharmaceutical Design

Cancer Stem Cell Based Targeted Therapy

Related Journals

Related Books

Related Articles